MedTrace Logo

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

NCT07315087 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-01-20

No results posted yet for this study

Summary

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

Conditions

  • SLE - Systemic Lupus Erythematosus
  • SSc-Systemic Sclerosis
  • IIM- Idiopathic Inflammatory Myopathies
  • ANCA Associated Vasculitis (AAV)
  • Connective Tissue Disease-Associated Thrombocytopenia
  • SLE-ITP

Interventions

BIOLOGICAL

QT-019C

universal allogeneic anti-CD19/BCMA CAR T-cells

Sponsors & Collaborators

  • Shanghai Xiniao Biotech Co., Ltd.

    collaborator INDUSTRY

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2029-01-01
Completion
2029-01-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07315087 on ClinicalTrials.gov